These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 38161197

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Optimized self-nanoemulsifying drug delivery system of atazanavir with enhanced oral bioavailability: in vitro/in vivo characterization.
    Singh G, Pai RS.
    Expert Opin Drug Deliv; 2014 Jul; 11(7):1023-32. PubMed ID: 24820316
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
    Sevinsky H, Zaru L, Wang R, Xu X, Pikora C, Correll TA, Eley T.
    Pediatr Infect Dis J; 2018 Jun; 37(6):e157-e165. PubMed ID: 29206748
    [Abstract] [Full Text] [Related]

  • 4. Atazanavir-loaded Eudragit RL 100 nanoparticles to improve oral bioavailability: optimization and in vitro/in vivo appraisal.
    Singh G, Pai RS.
    Drug Deliv; 2016 Jun; 23(2):532-9. PubMed ID: 24963752
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial.
    Colella E, Cattaneo D, Galli L, Baldelli S, Clementi E, Galli M, Lazzarin A, Castagna A, Rusconi S, Spagnuolo V.
    New Microbiol; 2018 Apr; 41(2):106-111. PubMed ID: 29498742
    [Abstract] [Full Text] [Related]

  • 10. Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.
    Biagi M, Badowski ME, Chiampas T, Young J, Patel M, Vaughn P.
    Int J STD AIDS; 2017 Jul; 28(8):766-772. PubMed ID: 27587601
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.
    Harris M, Ganase B, Watson B, Hull MW, Guillemi SA, Zhang W, Saeedi R, Harrigan PR.
    HIV Clin Trials; 2017 Jan; 18(1):39-47. PubMed ID: 28067119
    [Abstract] [Full Text] [Related]

  • 12. Identification of Mechanism and Pathway of the Interaction between the African Traditional Medicine, Sutherlandia Frutescens, and the Antiretroviral Protease Inhibitor, Atazanavir, in Human Subjects Using Population Pharmacokinetic (PK) Analysis.
    Muller AC, Ducharme MP, Kanfer I.
    J Pharm Pharm Sci; 2018 Jan; 21(1s):215s-221s. PubMed ID: 30158052
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
    Gianotti N, Seminari E, Guffanti M, Boeri E, Villani P, Regazzi M, Bigoloni A, Schira G, Tiberi S, Fusetti G, Lazzarin A, Castagna A.
    New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.
    Lê MP, Mandelbrot L, Descamps D, Soulié C, Ichou H, Bourgeois-Moine A, Damond F, Lariven S, Valantin MA, Landman R, Faucher P, Tubiana R, Duro D, Meier F, Legac S, Bourse P, Mortier E, Dommergues M, Calvez V, Matheron S, Peytavin G.
    Antivir Ther; 2015 Apr; 20(5):507-13. PubMed ID: 25599649
    [Abstract] [Full Text] [Related]

  • 18. Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients.
    Giacomelli A, Oreni L, Franzetti M, Di Cristo V, Colella E, Ridolfo AL, Galli M, Rusconi S.
    Antiviral Res; 2016 May; 129():52-57. PubMed ID: 26902109
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.